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Metastasis and chemoresistance in cancer are linked
phenomena, but the molecular basis for this link is
unknown. We uncovered a network of paracrine
signals between carcinoma,myeloid, and endothelial
cells that drives both processes in breast cancer.
Cancer cells that overexpress CXCL1 and 2 by tran-
scriptional hyperactivation or 4q21 amplification are
primed for survival in metastatic sites. CXCL1/2
attract CD11b+Gr1+ myeloid cells into the tumor,
which produce chemokines including S100A8/9
that enhance cancer cell survival. Although chemo-
therapeutic agents kill cancer cells, these treatments
trigger a parallel stromal reaction leading to TNF-a
production by endothelial and other stromal cells.
TNF-a via NF-kB heightens the CXCL1/2 expression
in cancer cells, thus amplifying the CXCL1/2-
S100A8/9 loop and causing chemoresistance.
CXCR2 blockers break this cycle, augmenting the
efficacy of chemotherapy against breast tumors
and particularly against metastasis. This network of
endothelial-carcinoma-myeloid signaling interac-
tions provides amechanism linking chemoresistance
and metastasis, with opportunities for intervention.
INTRODUCTION
Breast cancer remains the most common malignant disease in
women, with one million new cases diagnosed worldwide per
year, causing 400,000 deaths (Gonzalez-Angulo et al., 2007).
The vast majority of these deaths are due to metastatic disease.
Although the 5 year disease-free survival rate is 89% in patientswith well-treated localized breast cancer, the appearance of
metastatic disease is almost always a harbinger of eventual
cancer mortality. The median survival of breast cancer patients
with distant metastasis is between one and two years, and
only a quarter of such patients survive 5 or more years from diag-
nosis of metastases (Jones, 2008).
The two established forms of systemic therapy for metastatic
disease are hormonal treatments for hormone-dependent
(estrogen and/or progesterone receptor positive) cases and
cytotoxic chemotherapy for cases without hormone receptors.
Hormone-dependent breast cancers frequently become refrac-
tory to initially effective hormonal treatments, thus eventually
requiring chemotherapy as well. Trastuzumab, an antibody to
the extracellular domain of the receptor c-erbB2/HER2, often
augments the chemotherapy effect in cases overexpressing
this gene (Pegram et al., 2004). Although tumor shrinkage is
commonly accomplished on initial use of chemotherapy, the
eventual emergence of tumor regrowth in the original as well
as in new sites is common (Jones, 2008). On developing
progressive disease after initial chemotherapy, different chemo-
therapy drugs are usually offered to patients, but the odds of
response to subsequent administrations of chemotherapy
decline with each episode of response and progression. Ulti-
mately, pan-resistance occurs, which in association with the
progression of metastatic spread, an almost universally linked
process, is the cause of death (Gonzalez-Angulo et al., 2007).
Drug resistance in cancer can be cell-intrinsic (Poulikakos and
Rosen, 2011) or a combination of host and tumormediated path-
ways (Bergers and Hanahan, 2008; Ebos et al., 2009). In the case
of chemotherapeutic agents, resistance develops because of
both pre-established intrinsic mechanisms as well as those
acquired de novo during the course of the treatment (Gonza-
lez-Angulo et al., 2007). Recent evidence points to tumor
microenvironment components as potential participants in the
generation of chemoresistance (Denardo et al., 2011; GilbertCell 150, 165–178, July 6, 2012 ª2012 Elsevier Inc. 165
Figure 1. CXCL1/2 Mediate Mammary Tumor Growth and Lung Metastasis
(A) CXCL1 and CXCL2 expression in 615 primary breast cancers based on microarray gene expression data sets. Correlation between the two genes was
determined by Pearson’s correlation coefficient (n = 615, r = 0.53, p < 2.2 3 1016). p value was determined by Student’s t test.
(B) Breast cancer tissue microarray (TMA) samples composed of normal breast tissue, primary breast tumors and metastases (LN from lymph node and lung
metastases) from patients analyzed by FISH. Signals in green correspond to 4q centromeric reference probe and signals in red correspond to CXCL1/2 probes.
Scale bar, 2.5 mm.
(C) Schematic representation of breast cancer progression in orthotopic allograftmodel. PyMTmammary cancer cells were isolated fromMMTV-PyMTmammary
tumors, transduced with shRNA control or shCxcl1/2, and transplanted into syngeneic mice.
(D) Growth curves of tumors from control and shCxcl1/2 PyMT-F cells. Data are averages ± SEM; n = 6 mice per group.
(E) Spontaneous lung metastasis determined by H&E staining of lung sections at week 9 after tumor inoculation at endpoint. Scale bars,10 mm.
(F) Quantitation of lung metastasis determined by automated counting of foci per field of view (FOV). Data are averages ± SEM; n = 6 mice per group. p values
were determined by Student’s t test.
(G) Schematic representation of breast cancer progression in orthotopic xenograft model. LM2 metastatic breast cancer cells were implanted into immuno-
deficient NOD-SCID mice. Mammary tumor growth and lung metastasis were determined.
(H) Growth curves of tumors from LM2 cells transduced with control or CXCL1/2 shRNA. Data are averages ± SEM. Control, n = 13, shCXCL1/2, n = 7.
(I) Representative histology images of spontaneous lung metastasis detected by vimentin immunostaining. Scale bars, 60 mm.
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and Hemann, 2010; Roodhart et al., 2011; Shaked et al., 2008;
Shree et al., 2011). However, an integrated understanding of
acquired drug resistance in the context of inputs from tumor
and its microenvironment is lacking. Such insights could be
critical for designing more effective therapies to overcome resis-
tance and improve outcome from a palliative to curative clinical
response in cancer.
Clinically as well as biologically, metastasis is intricately linked
with resistance to chemotherapy (Hu et al., 2009; Morris et al.,
2009). Biologically, less than 0.1% of the circulating cancer cells
are estimated to withstand the harsh stresses of infiltrating and
colonizing distant metastatic sites (Weiss, 2000). Similarly,
a very small fraction of cells exposed to genotoxic stress can
survive and outgrow under repeated cycles of chemotherapy.
This combined clinical and biological problem prompted us to
ask whether both metastatic and chemotherapeutic stresses
might select for cancer cells with a common set of survival
advantage mechanisms. We uncovered a paracrine network,
with the chemokines CXCL1 and 2 at its core, that mediates
lungmetastasis and chemoresistance in breast cancer.We iden-
tified the signals from cancer cells that trigger this paracrine
cascade, the specific stromal cell types that respond to these
signals, the cancer cell survival factors delivered by the stromal
cells, and the survival response of cancer cells to these stromal
factors. We delineated how chemotherapy triggers a parallel
reaction in the stroma and amplifies this paracrine network
making therapy less effective. Blocking this axis with CXCL1/2
receptor inhibitors in combination with chemotherapy markedly
reduced metastatic burden in preclinical models, addressing
the key problem of why chemotherapeutic treatments fail and
lead to relapse.
RESULTS
CXCL1/2 Mediate Mammary Tumor Growth
and Lung Metastasis
Several observations provided a rationale to explore the poten-
tial role of CXCL1/2 in breast cancer progression and metastatic
recurrence to the lungs. CXCL1 emerged among a set of genes
whose expression is associated with lung relapse in breast
tumors, including tumors that had not been exposed to prior
chemotherapy (Minn et al., 2007; Minn et al., 2005), and as
a gene that increases the aggressiveness of circulating breast
tumor cells (Kim et al., 2009). CXCL1 and 2 are 90% identical
by amino acid sequence and signal through the same receptor
CXCR2 (Balkwill, 2004). Indeed, CXCL1 and CXCL2 showed
a similar expression pattern in a combined cohort of 615 primary
breast cancers (Figure 1A). Copy number alterations at 4q21(J) Quantitation of lung metastatic burden determined by automated counting o
p values was determined by Student’s t test.
(K) Schematic representation of lung colonization assay in xenograft model. Lucif
injected intravenously and monitored over time by noninvasive BLI.
(L) BLI quantification of lung colonization ability of control or shCXCL1/2 LM2 ce
Student’s t test.
(M) Representative BLI images of mice with lung metastasis.
(N) Cancer cells in the lungs stained for vimentin expression.
See also Figure S1.occur in breast cancer (Beroukhim et al., 2010) and engulf 15
genes in the amplification peak, including CXCL1-8. Fluores-
cence in situ hybridization (FISH) of human tissue samples
showed that CXCL1 and CXCL2 were amplified in 7.5% of
primary breast tumors and in 19.9% of metastases (Figures 1B
and S1A available online). These results suggested that
increased copy number contributes to the higher CXCL1/2
expression in invasive breast tumors and metastases. Addition-
ally, high expression of CXCL1 in breast tumors without gene
amplification is also possible (Bie`che et al., 2007).
Prompted by these findings we investigated the role of CXCL1
and 2 in breast cancer. We utilized two independent experi-
mental systems. First, a syngeneic transplant system with cell
lines derived frommammary tumors driven by a polyoma middle
T transgene in two different MMTV-PyMT mouse strains, FVB/N
(PyMT-F for short) and C57BL/6 (PyMT-B) (Stewart and Abrams,
2007). Second, a xenograft model to orthotopically implant LM2-
4175 lung metastatic cells (LM2 for short) was derived from the
MDA-MB-231 human breast cancer cell line (Minn et al., 2005).
LM2 cells showed upregulation of CXCL1/2 compared to the
parental line (Figure S1B). PyMT-F and LM2 cells grew aggres-
sively in the mammary fat pad and metastasized to the lungs.
Knockdown ofCXCL1 and 2 using two independent shRNA hair-
pins (Figures S1C and S1D) significantly reduced mammary
tumor growth in all three models (Figures 1C, 1D, 1G, and 1H,
S1E, and S1F) This decrease was associated with reduced
metastasis in the lungs (Figures 1E, 1F, 1I, 1J, and S1G). Similar
results were obtained upon size-matching the knockdown
tumors to controls (Figures S1H and S1I). Furthermore, lung
colonization assays by tail-vein injection of LM2 cells confirmed
that the effect of CXCL1/2 depletion on metastasis is not solely
a consequence of decreased tumor burden (Figures 1K–1N).
Interestingly, among other CXCR2 ligands that we tested,
CXCL3 knockdown in LM2 cells contributed to tumor growth
but not metastasis (Figures S1K–S1M). We concluded that
CXCL1/2 play a prominent role in breast cancer progression
and metastasis.
CXCL1/2 Recruit Myeloid Cells to Mammary Tumors
Reduction in CXCL1/2 levels in the LM2 xenograft and PyMT
transplantation models was associated with a significant
increase in apoptosis in the tumors (Figures 2A and 2B).
However, CXCL1/2 knockdown was not accompanied by any
visible changes in apoptosis in vitro or in angiogenesis and cell
proliferation rates in tumors (Figures S2A–S2E). The function of
CXCL1/2 is primarily mediated by binding to the G protein
coupled receptors, CXCR2 and, in some instances, CXCR1
and DARC (Balkwill, 2004). Compared to the high levels off number of foci per FOV. Shown are averages ± SEM; n = 5 mice per group.
erase labeled MDA231-LM2 cells transduced with control or shCXCL1/2 were
lls. Data are averages ± SEM; n = 7 per group. p values were determined by
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Figure 2. Carcinoma-Derived CXCL1/2 Supports Cancer Cell Survival and Recruit Granulocytic Myeloid Cells to Tumors
(A and B) Representative images and quantification of apoptosis in mammary tumors analyzed by cleaved caspase-3 staining. Mouse mammary glands were
injected with LM2 cells (A and B) or PyMT-F cells (B) expressing shRNA control or shCXCL1/2 and analyzed at endpoint (LM2, 6 weeks; PyMT-F, 9 weeks after
tumor implantation). Scale bar, 30 mm. Data are averages ± SEM; n = 4 mice per group. p values were calculated by Student’s t test.
(C) Expression of the indicated genes frommicroarray gene expression analysis in nontumor humanmammary epithelial cell lineMCF10A, parental MDA-MB-231
breast cancer cells and lung metastatic lines derived from MDA-MB-231 (Minn et al., 2005).
(D) Flow cytometric analysis of recruited myeloid cells in tumors formed by LM2 cells transduced with either control shRNA or shCXCL1/2 at 5 weeks after tumor
inoculation. A representative gating is shown. Numbers indicate either CD11b+Ly6G+ or CD11b+Ly6C+ cells in the quadrant expressed as percentages of total
CD45+ leukocytes from the same tumor. Results are representative of three independent experiments (n = 3).
(E) Expression of Cxcr2 receptor in sorted subpopulations of LM2 tumors determined by qRT-PCR. Error bars represent 95% confidence interval for qRT-PCR
analysis. Data are representative of two independent experiments.
See also Figure S2 and Tables S1 and S2.CXCL1/2 expression in lung metastatic cell lines, the expression
of CXCR1, CXCR2, and DARC was negligibly low both at
the RNA and protein levels (Figure 2C and Figure S2F and Mu¨ller
et al., 2001). Based on these results, we postulated that CXCL1/2
mediates tumor cell survival via paracrine mechanisms.
CXCR2 receptor is expressed by several stromal cell types
such as endothelial and myeloid cells (Murdoch et al., 2008).
Using a combination of immunostaining and FACS, we did
a comprehensive analysis of major cell types in the tumor micro-
environment whose abundance changed upon CXCL1/2 knock-
down in the LM2 xenograft and PyMT-F transplant models. A
significant reduction in CD11b+Gr1+ myeloid cells was observed
inCXCL1/2 knockdown tumors in both models (Figures S2G and
S2H). Myeloid-derived suppressor cells (MDSC) represent a
heterogeneous group including precursors for neutrophils and
monocytes that express both CD11b and Gr1 (Gabrilovich and
Nagaraj, 2009). Gr1+ in mice includes cells that express the
macrophage marker Ly6C and cells that express the neutrophil
marker Ly6G (Ostrand-Rosenberg and Sinha, 2009). Detailed
characterization of the myeloid cells showed a decrease in the168 Cell 150, 165–178, July 6, 2012 ª2012 Elsevier Inc.CD11b+Ly6G+ granulocytic MDSC population in CXCL1/2
knockdown tumors compared to controls (Figures 2D and S2I).
No appreciable decrease was observed in the CD11b+Ly6C+,
F4/80+ macrophages, SMA+ myofibroblast, Ter119+ erythroid
cells, or endothelial cells in the CXCL1/2 depleted tumors
(Figures S2J–S2P, Table S1, and data not shown). In line with
our hypothesis, CD11b+Gr1+ cells and specifically the CD11b+
Ly6G+ subpopulation expressed CXCR2 (Figures 2E and S2Q).
Within the recruited CD11b+Ly6G+ population in the PyMT
immunocompetent transplant tumors, 6%, 12%, and 25% of
the cells expressed CD80, F4/80, and Sca1, respectively,
and a minority expressed CD86, CD117, IL4Ra, VEGFR1, and
CD34 (Table S2). Sca1, amarker of the hematopoietic stem cells,
was expressed in CD11b+Ly6G+ populations, indicating poten-
tial progenitor-like phenotype of the tumor granulocytic cells
recruited by CXCL1/2 (Table S2).
Interestingly, a reduction both inmonocytic CD11b+Ly6C+ and
granulocytic CD11b+Ly6G+ cells occurred in the lungs of mice
bearing CXCL1/2 depleted tumors with minimal changes in the
number of F4/80+ macrophages (Figures S2R–S2T). Compared
to the myeloid components, lymphocytic cells represented
a minority of leukocytes infiltrated in the immunocompetent
PyMT transplanted tumors (Table S1). CXCL1/2 depleted tumors
showed a decrease in CD4+ and CD8+ lymphocytes, no major
change in gd-TCR+ and CD25+ T regulatory cells, and moderate
increases in B220+ lymphocyte and CD49b+ NK cell numbers
(Table S1). Given the low numbers and small differences within
lymphocytic populations in the tumors, we chose to focus on
CD11b+Gr1+ cells that are the predominant cell type recruited
by CXCL1/2 in the tumor microenvironment in multiple models.
CXCL1/2 Promote Metastasis through Myeloid-Cell-
Derived S100A8/9
Results from our functional analysis suggested that myeloid cell
types recruited by CXCL1/2 might provide paracrine factors that
support the survival of cancer cells. To identify such factors, we
analyzed human breast tumor gene expression data sets for
genes that are expressed in association with CXCL1 (Figure 3A).
Focusing on paracrine mediators, we filtered genes encoding
cell surface and secreted products. Analysis of 615 breast
tumors from three independent data sets yielded 43 such genes
that correlated withCXCL1with a coefficient > 0.3 (Figure 3A and
Table S3). These genes showed a predominance of chemokines
(40%) and cytokines (21%). Similar analysis of a data set
generated from 67 metastases from breast cancer patients
showed a 61% overlap in CXCL1-associated genes between
primary breast tumors and metastases (Figure 3B and Tables
S3 and S4).
To identify cancer cell survival factors derived from the
recruited myeloid cells, we identified candidates that are abun-
dantly expressed in tumor-derived CD11b+Gr1+ cells and are
not of epithelial origin (Figures 3C and 3D and Figure S3A).
S100A8 and A9 fulfilled these criteria. S100A8/9 are low molec-
ular weight calcium binding proteins that are associated with
chronic inflammation and cancer (Gebhardt et al., 2006).
S100A8/9 bind to Toll-like receptor 4 (TLR4) and RAGE (receptor
for advanced glycation end products), which activate diverse
signaling cascades (Gebhardt et al., 2006; Vogl et al., 2007).
Both TLR4 and RAGE are expressed in breast cancer cells
(Bos et al., 2009; Hsieh et al., 2003).
To determine whether myeloid S100A8/9 stimulate tumor
growth and metastatic phenotype of breast cancer cells, we iso-
lated bone marrow cells from S100A9+/+ and S100A9/ mice
(Hobbs et al., 2003) and transplanted them into irradiated immu-
nocompromised mice. In addition to lacking S100A9, S100a9/
bone-marrow-derived cells fail to express S100A8, which is the
heterodimeric partner of S100A9 (Figure S3B) (Hobbs et al.,
2003). After confirming successful engraftment of S100a9+/+ or
S100a9/ bone marrow with an efficiency of > 98% (Fig-
ure S3C), we implanted LM2 cancer cells in the mammary fat
pads of these mice. Mammary tumor growth and lung metas-
tasis were significantly reduced in mice transplanted with
S100a9/ bone marrow compared to the S100a9+/+ counter-
part (Figures 3E–3G).
To confirm these results in a different system, we stably
reduced the expression of S100a8/9 in MPRO, a murine bone-
marrow-derived promyelocytic cell line (Figure S3D) that
expresses both CD11b and Gr1 (Tsai and Collins, 1993). Coin-jection of wild-type MPRO cells with LM2 cancer cells enhanced
mammary tumor growth and lung metastasis, an effect that was
significantly blunted by S100a8/9 knockdown in the MPRO cells
(Figures S3E and S3F). Furthermore, the enforced expression of
S100a8/9 in LM2 cells (Figures S3G and S3H) rescued the
CXCL1/2 knockdown phenotype of reduced tumor growth and
metastasis (Figures 3H, 3I, and S3I). Together, these results
suggest that S100A8/9 mediate the prometastatic effect of
CXCL1/2 in our models.
Based on the accumulating evidence of a role of S100A8/9 in
breast cancer metastasis in animal models, we sought evidence
for this link in clinical samples. We immunostained tissue micro-
arrays composed of lungmetastasis samples frombreast cancer
patients with an antibody recognizing human S100A8/9 (Fig-
ure 3J). Kaplan Meier analysis showed that patients with high
S100A8/9 in the metastatic nodules had a significantly shorter
overall survival compared to low S100A8/9 (p value = 0.01) (Fig-
ure 3K). Collectively our results suggest that CXCL1/2 from
breast cancer cells recruit myeloid producers of S100A8/9,
which in turn promote breast cancer metastasis.
S100A8/9 Promotes Breast Cancer Cell Survival
under Chemotherapy
We investigated whether S100A8/9 in tumors are linked to
enhanced cancer cell survival. Tumor-bearing mice transplanted
with S100a9/ bone marrow showed a marked increase in the
number of apoptotic cells in the mammary tumors and the lung
(Figure 4A). The requirement of S100A8/9 in cell survival was
even more evident when tumor-bearing mice were treated with
chemotherapeutic agents as an inducer of cell death (Figures
4B and 4C and S4A).
Similar numbers of CD11b+ and CD68+ myeloid cells were
present in tumors and lung nodules from mice transplanted
with either S100a9/ or S100a9+/+ bone marrow cells (Fig-
ure S4B and data not shown). This result ruled out the possibility
that higher apoptotic rates in the S100A9/ group were due to
a defective accumulation of myeloid cells (Hiratsuka et al., 2008).
Consistent with the survival advantage provided by S100A8/9
in vivo, coculture of cancer cells with bone-marrow-derived
CD11b+Gr1+ cells protected cancer cells from doxorubicin-
induced apoptosis (Figure 4D). However, this protection was
more limited in coculture with CD11b+Gr1+ cells derived from
S100A9/ marrow (Figure 4D), confirming that the prosurvival
properties of myeloid factors under stress chemotherapy condi-
tions are partly due to S100A8/9.
Binding of S100A8/9 to receptors RAGE and TLR4 can acti-
vate diverse signaling cascades (Gebhardt et al., 2006; Ichikawa
et al., 2011; Vogl et al., 2007). S100A8/9 addition only weakly
activated NFkB in LM2 breast cancer cells and we detected no
activation of the Akt or STAT3 pathways (Figure S4C and data
not shown). Using blot arrays that detect phosphorylation of
46 different protein kinases, we found that S100A8/9 cause
activation of ERK1/2, p38 MAPK, and p70S6K in LM2 cells
(Figures 4E and S4D), as confirmed by immunoblotting (Figures
S4E and S4F). Addition of an ERK1/2 inhibitor (FR180204)
or a p70S6K inhibitor (PF4708671) abolished the chemo-protec-
tive effect of S100A8/9, whereas addition of a p38 inhibitor
(SB203580) showed partial effect (Figure 4F), suggesting thatCell 150, 165–178, July 6, 2012 ª2012 Elsevier Inc. 169
Figure 3. CXCL1/2 Promote Metastasis through Myeloid-Cell-Derived S100A8/9
(A and B) Gene ranking according to correlation with CXCL1 expression. Expression data from breast cancer primary and metastases microarray data sets.
Genes were filtered based on extracellular localization to identify paracrine mediators. The list on the right shows genes that correlate highest with CXCL1.
Complete list of CXCL1 correlating genes in Tables S3 and S4.
(C) Expression of the top seven CXCL1-associated genes in (A) in the sorted CD11b+Gr1+ cells compared to unsorted tumor determined by qRT-PCR analysis
from LM2 breast cancer model andMMTV-PyMT autochthonous mammary cancer model. Error bars represent 95% confidence interval. Data are representative
of two independent experiments.
(D) Expression of top seven CXCL1-associated genes in breast cancer cell lines based on microarray gene expression data.
(E) LM2 tumor growth curves in mice transplanted with either S100a9+/+ or S100a9/ bonemarrow. Data points show averages ± SEM; n = 19 tumors per group.
p value was determined by Student’s t test.
(F and G) Representative images and quantitation of metastatic cells in lungs detected by vimentin immunohistochemistry at 60 days after inoculation of LM2
tumors, in mice that were transplanted with S100a9+/+or S100a9/ bone marrow. Scale bar, 60 mm. Data points show averages ± SEM; n = 4–6 mice per group.
p value was determined by Student’s t test.
(H and I) Lung colonization by LM2 cells transduced with control shRNA or shCXCL1/2, with or without ectopic expression of S100a8/9. Lung colonization was
assessed by noninvasive BLI at 4 weeks after tail-vein injection of the cells. (H) Normalized BLI quantification. (I) images represented by photon flux of lung
colonization ability. Data are averages ± SEM; n = 4–6 per group. ns, not significant. p value was determined by two-tailed Wilcoxon rank-sum test.
(J) Representative TMA cores containing lung metastasis samples from breast cancer patients stained for total S100A8/9.
(K) Kaplan-Meier overall survival analysis on breast cancer patients classified by total S100A8/9 expression in lung metastasis (see J) n = 23 for S100A8/9 low
group, n = 17 for S100A8/9 high group. p values were calculated by log-rank test.
See also Figure S3 and Tables S3 and S4.
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Figure 4. S100A8/9 Promotes Breast Cancer Cell Survival under Chemotherapy
(A) Quantitation of apoptosis by cleaved caspase-3 staining in tumors and TUNEL assay in lungs in mice transplanted with S100a9+/+or S100a9/ bone marrow
at 60 days after LM2 tumor inoculation into themammary fat pad. Data are averages ±SEM; n = 4–6mice per group. p valueswere determined by Student’s t test.
(B and C) Representative images and quantification of apoptosis by cleaved caspase 3 staining in LM2 tumors from mice transplanted with either S100a9+/+or
S100a9/ bone marrow and subsequently treated with a combination of doxorubicin and cyclophosphamide chemotherapy (AC regimen, chemo) once weekly
for 3 weeks. Scale bar, 32 mm. Data are averages ± SEM; n = 5–6 tumors per group. p values were determined by Student’s t test.
(D) TUNEL analysis detecting apoptotic cancer cells in coculture assay. LM2 cancer cells were cultured alone or overnight in the presence of S100a9+/+ or
S100a9/ bone marrow cells and subsequently treated with chemotherapeutic drug (Chemo), doxorubicin (0.8 mM). Data are average ± SEM of triplicates.
p values determined by Student’s t test.
(E) Screening of signaling pathways activated by S100A8/9 in LM2metastatic cancer cells by probing human phosphokinase array with lysates from cells treated
with either PBS or 10 mg/ml recombinant S100A8/9. Shorter exposure of the same blot shown in S4. Proteins showing increased phosphorylation upon S100A8/9
treatment are highlighted.
(F) TUNEL analysis detecting apoptotic cancer cells in coculture assay upon pharmacological inhibition of p38, p70S6K and ERK pathways in the presence of
recombinant S100A8/9. LM2 cancer cells were pretreated with 10 mg/ml of S100A8/9 for 1 hr and subsequently treated with doxorubicin (0.8 mM, chemo) either
alone or in the presence of 5 mMof p38 inhibitor SB203580 or 10 mMof p70S6K inhibitor PF4708671 or 10 mMof ERK inhibitor FR180204 for 16h. LM2 cells treated
with saline were used as controls. Quantification of apoptosis was done by calculating the percentage of TUNEL+/DAPI+ cells per FOV. Data are shown as
average ± SEM from triplicates. * p = 0.004, ** p = 0.02, *** p = 0.04, ****p = 0.01. p values were determined by Student’s t test.
See also Figure S4.the ERK1/2 and p70S6K signaling mediate the prosurvival effect
of S100A8/9 in metastatic cells.
The CXCL1/2–S100A8/9 Survival Axis Is Hyperactivated
by Chemotherapy
Most patients who develop metastatic disease receive chemo-
therapy at some point in the management of their illness. Tumor
shrinkage—partial or, less commonly, complete remissions—is
usually accomplished, but these benefits are transient, and
most patients eventually develop chemotherapy-resistant,
widely disseminated cancer (Gonzalez-Angulo et al., 2007;
Jones, 2008). We hypothesized that the CXCL1/2-S100A8/9
survival axis could nurture tumor cells under chemotherapeutic
stress thereby selecting for aggressive metastatic progeny. Toaddress this question, we treated mice bearing LM2 tumors
with doxorubicin and cyclophosphamide (AC regimen), a
commonly used chemotherapy combination in the clinic. MDA-
MB-231, the parental breast cancer cell line from which LM2
was derived, was originally isolated from pleural effusion of a
patient whowas resistant to AC and 5-fluorouracil chemotherapy
and had relapsed (Cailleau et al., 1974). Chemotherapy treatment
of mice bearing LM2 tumors initially resulted in significant
apoptosis and a concomitant delay in tumor growth (Figures 5A
and 5B). However, after subsequent rounds of chemotherapy,
tumors became refractory, as evidenced by a reduction in
apoptosis and resumed tumor growth (Figures 5A and 5B).
To investigate the involvement of the CXCL1/2-S100A8/9
in cancer cell survival during chemotherapy challenge, weCell 150, 165–178, July 6, 2012 ª2012 Elsevier Inc. 171
Figure 5. CXCL1/2 Paracrine Axis Is Hyperactivated upon Chemotherapy Treatment
(A) Tumor growth in mice treated with saline vehicle or a combination of doxorubicin and cyclophosphamide chemotherapy (AC chemo). The treatment was
initiated once LM2 tumors reached 300 mm3 and was repeated once weekly. Data represent averages ± SEM; n = 6–8mice per group. p values were determined
by Student’s t test.
(B) Apoptosis determined by TUNEL staining in tumors treated with vehicle or AC chemotherapy for 3 days (early) or 8 days (late) both using the same treatment
regimen. Data represent averages ± SEM; n = 3–5 mice per group. p values were calculated by Student’s t test. *p = 0.02, **p < 0.0001.
(C) CXCL1/2 expression in whole tumors harvested from mice treated with saline vehicle or AC chemotherapy for 8 days. Data represent averages ± SEM;
n = 6–8 mice per group. p values were determined by Student’s t test.
(D) Representative CXCL1 expression in whole tumors analyzed by immunohistochemistry harvested from mice treated with saline vehicle or AC chemotherapy
(prolonged treatment) from two independent cohorts of three mice each. Scale bar, 70 mm.
(E) Quantitation of S100A9 positive cells in tumors from control and AC chemotherapy-treated mice (prolonged treatment). Data presented are average numbers
of S100A9 positive cells per FOV ± SEM; n = 4–5 mice/group. Data representative of three independent experiments.
(F) Expression of S100a8 and S100a9 in sorted subpopulations of LM2 tumors after chemotherapy treatment determined by qRT-PCR. Error bars represent 95%
confidence interval. Data representative of two independent experiments.
(G) Immunohistochemical analysis of S100A8/9 in tumors from breast cancer patients before and after AC chemotherapy treatment. Representative images of
scored S100A8/9 sections are shown. Scale bar, 60 mm.
(H) S100A8/9 expression score in paired patient tumor samples, before and after chemotherapy. Data represent expression score. n = 40. p values determined by
Wilcoxon’s paired test, comparing pre- and posttreatment levels from each patient.
See also Figure S5 and Table S5.analyzed the expression of CXCL1 and CXCL2 in AC chemo-
therapy-treated tumors. AC-treated tumors significantly upregu-
lated CXCL1/2 expression (Figures 5C and 5D) and this effect
was associated with increased recruitment of S100A9-express-
ing cells (Figure 5E) and CD11b+Ly6G+ granulocytic cells (Fig-
ure 5F). CXCL1/2 upregulation in the LM2 tumors was also
observed with another commonly used chemotherapeutic
agent, paclitaxel (Figure S5A). In addition to CXCL1/2 and
S100A8/9, the CXCL1-associated chemokine genes CCL20
and CXCL3 were also highly expressed in response to chemo-
therapy (Figure S5B). Although induction of CXCL chemokines
occurs during chemotherapy-induced senescence (Coppe´
et al., 2008), there was no discernible increase in senescence
in LM2 tumors upon AC chemotherapy treatment (Figures S5C172 Cell 150, 165–178, July 6, 2012 ª2012 Elsevier Inc.and S5D). Together, these results suggest that chemotherapy
activates a burst of paracrine factors including the cancer cell
survival axis CXCL1/2-S100A8/9 that selects for cancer cells
that can resist chemotherapy.
S100A8/9 Association with Resistance to Perioperative
Chemotherapy
Neoadjuvant chemotherapy—the use of cytotoxic drugs prior to
surgery for primary breast cancer—is an option for patients with
operable disease. This has long been the standard approach for
patients with locally advanced primary disease in an effort to
shrink the tumor and thereby make complete tumor removal
possible. Although these treatments usually cause tumor volume
regression, some cases are chemotherapy-resistant de novo
(Gonzalez-Angulo et al., 2007). To addresswhether theCXCL1/2-
S100A8/9 survival loop is activated in cancer patients with
primary disease, we stained matched breast tumor sections
from a cohort of patients before and after chemotherapy treat-
ment. Consistent with our experimental models, a significant
increase in S100A9-expressing cells was observed in breast
cancers after chemotherapy treatment (Figures 5G and 5H and
Table S5). In contrast, Fascin that is part of a lung metastasis
gene signature (Minn et al., 2005) did not show the same trend
upon chemotherapy treatment as S100A8/9 (Figure S5E), further
confirming the specificity of the association of S100A8/9 with
chemotherapy resistance.
Chemotherapy Induces TNF-a to Boost
the CXCL1/2-S100A8/9 Axis
Hyperactivation of the CXCL-S100A8/A9 loop upon chemo-
therapy treatment prompted us to explore the mechanism
behind the therapy-induced CXCL1/2 upregulation. In our exper-
imental models, enhanced expression of CXCL1/2 in response
to chemotherapy was not due to additional amplification of the
locus as determined by FISH analysis (Figure S6A). Direct treat-
ment of LM2 cells with the chemotherapeutic agents did not
induce CXCL1/2 expression (Figure S6B and data not shown).
However, LM2 tumor cells incubated with conditioned media
from chemotherapy-treated primary endothelial cells or primary
bone-marrow-derived cells showed a significant increase in
CXCL1/2 expression (Figures 6A and S6B).
CXCL1/2 are target genes of the NFkB/STAT1 pathway (Amiri
and Richmond, 2003). Among a panel of prototypical activators
of the NFkB/STAT1 pathway that we assayed by qRT-PCR,
TNF-a was strikingly induced in endothelial cells upon doxoru-
bicin chemotherapy treatment (Figure 6B). Moreover, we
observed a 10-fold increase in TNF-a expression in purified
lung endothelial cells from LM2 tumor-bearing mice systemically
treated with AC chemotherapy (Figures 6C and 6D). TNF-a
induction in response to chemotherapy also occurred in smooth
muscle and bone-marrow-derived cells (Figure 6E) suggesting
that TNF-a release is a general response to chemotherapy in
different stromal cell types. NFkB activation by TNF-a stimulated
the expression of CXCL1/2 in LM2 tumor cells, as determined
with the use of NFkB pathway inhibitor (Nemo binding domain
peptide or NBD) (Figure 6F). Thus, TNF-a from chemotherapy-
activated stroma can boost the CXCL1/2-S100A8/9 loop. Treat-
ment with anti-TNF-a antibody infliximab reduced recruitment of
S100A9-expressing cells in chemotherapy-treated mammary
tumors (Figures 6G and 6H). These tumors were formed with
cell line CN34-LM1 derived from the pleural fluid of a stage IV
breast cancer patient whose disease had progressed on therapy
(Tavazoie et al., 2008). CN34-LM1 is more indolent than LM2 and
allows for longer-term tumor growth experiments.
Consistent with our hypothesis, a significant increase in TNF-a
immunostaining was observed in patient samples after neoadju-
vant AC chemotherapy treatment (Figures 6I–6K) and in LM2
mammary tumors in mice treated with AC chemotherapy (Fig-
ure S6C). Importantly, histopathological analysis revealed that
cells from the tumor microenvironment, specifically lymphatic
and blood vessels and fibroblast-rich stroma, showed strong
TNF-a staining after chemotherapy (Figures 6J and S6D).Blocking CXCL1 Signaling Increases the Effectiveness
of Chemotherapy
Our findings suggest that a self-defeating consequence of
at least some chemotherapy drugs is the release of potent
proinflammatory cytokines such as TNF-a from stromal
sources. Such proinflammatory bursts can boost the CXCL1/2-
S100A8/9 survival axis and facilitates the expansion of chemore-
sistant breast cancer cells. These results presented us with an
option of targeting the tumor microenvironment in order to
sensitize breast cancer cells to chemotherapy and to the stress
of invading and colonizing distant tissues. Therefore, we utilized
antagonists of CXCR2, the primary receptor for CXCL1/2,
because derivatives of these pharmacological inhibitors are in
clinical trials for chronic inflammatory diseases and show no
major toxicity with long-term usage (Chapman et al., 2009).
Furthermore, targeting the immune microenvironment would
be an attractive option because of the potentially low selective
pressure for mutations and epigenetic changes on the stroma
compared to the cancer cell genomes.
Based on this rationale, we designed preclinical trials in xeno-
graft mice implanted with either of the two independent meta-
static breast cancer cell lines, MDA231-LM2 and CN34-LM1.
The mice were treated with a combination of AC chemotherapy
and CXCR2 antagonist starting after lung metastasis was
detectable by bioluminescence imaging (BLI) (data not shown).
Tumor-bearing mice treated with AC chemotherapy alone
showed a reduction in tumor growth (Figures 7A and 7B, S7A,
and S7B). However, metastatic cells were not completely elimi-
nated andmicrometastases were detected throughout the lungs
(Figures 7C and 7D). As a single agent, CXCR2 inhibitor had
partial to no effect depending on the model system. However,
when AC was combined with the CXCR2 inhibitor, lung meta-
static burden was markedly reduced and the interaction
between the drugs exhibited synergism (Figures 7C and 7D).
Together, these results highlight the potential of targeting the
CXCL1/2-S100A8/9 axis thereby sensitizing distant metastases
to standard of care chemotherapy.
DISCUSSION
A Three-Way Paracrine Axis Underlying
Chemoresistance and Metastasis
The major impediments to cure advanced breast cancer are
the emergence of pan-resistance to all known chemotherapy
drugs and the development of widely metastatic disease, two
phenomena that are closely linked clinically (Gonzalez-Angulo
et al., 2007). In addressing this challenge, our work links
CXCL1/2 and S100A8/9 as functional partners of a paracrine
loop between breast cancer cells and CD11b+Gr1+myeloid cells
that supports the survival of cancer cells facing the rigors of
invading newmicroenvironments or the impact of chemotherapy
(Figure 7E). Therapeutically targeting such commonmediators of
chemoresistance and distant relapse would be of interest
because these are the two main clinical challenges after primary
tumor resection.
The critical role of the microenvironment in tumor progression
and response to therapy is being increasingly recognized
(Condeelis and Pollard, 2006; Denardo et al., 2011; Gilbert andCell 150, 165–178, July 6, 2012 ª2012 Elsevier Inc. 173
Figure 6. TNF-a from Chemotherapy-Activated Stroma Boosts the CXCL1/2 Survival Axis
(A) CXCL1/2 expression in MDA231-LM2 cancer cells either alone (–) or in the presence of conditioned media from primary human umbilical vein endothelial cells
(HUVEC) that were either untreated (control) or treated with 0.8 mMdoxorubicin (chemo), as determined by qRT-PCR. Data represent average expression ± SEM.
(B) Heatmap representing expression changes in inflammatory cytokines in HUVEC treated with doxorubicin (0.8 mM). Heatmap generated by conversion of
qRT-PCR data that was normalized to b2M as housekeeping gene control.
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Hemann, 2010; Shree et al., 2011; Tan et al., 2011). The present
work sheds light on how the tumor microenvironment responds
to chemotherapy with hyperactivation of a TNF-a-CXCL1/2-
S100A8/9 paracrine axis for cancer cell survival under stress.
Recent reports (Denardo et al., 2011; Gilbert and Hemann,
2010) and the present work show that chemotherapy induces
a storm of cytokines and chemokines in the tumor microenviron-
ment, many of which might be linked to chemoresistance. Our
current findings suggest that this cytokine burst includes
TNF-a induced in several components of the tumor micro-
environment after chemotherapy treatment. An undesirable
consequence of the stromal TNF-a is to further boost CXCL1/2
expression in breast cancer cells. A higher level of CXCL1/2
then drives the paracrine loop involving myeloid-cell-derived
S100A8/9 to enhance cancer cell survival (Figure 7E). An
adverse cycle involving TNF-a-CXCL1/2-S100A8/9 could thus
be expanded in response to chemotherapy. Such a paracrine
survival network could be beneficial to cancer cells under stress
both in the primary tumor and at distant metastatic sites. Once
initiated, this chemo-protective program could become self-
sustaining, leading to the enrichment of residual aggressive
clones able to resist chemotherapy and thrive in the lung paren-
chyma and elsewhere.
Biological and Clinical Implications
Several additional insights emerge from this work. CD11b+Gr1+
myeloid cells are a heterogeneous group with previously identi-
fied roles in tumor angiogenesis and T cell immuno-suppression
(Gabrilovich and Nagaraj, 2009; Ostrand-Rosenberg and Sinha,
2009; Shojaei et al., 2007). Our study delineates a role for the
CD11b+Gr1+ cells in mediating metastatic breast cancer cell
survival through the production of S100A8/9. In addition to acti-
vating MAPK pathways (Gebhardt et al., 2006; Ichikawa et al.,
2011), we find that S100A8/9 activate p70S6K as contributors
to the prosurvival effect of S100A8/9 in these cells. In line with
our findings, recent Phase 2 study in breast cancer patients
showed that nonresponders of neoadjuvant chemotherapy and
patients with residual disease had significantly higher circulating
MDSC levels than did responders (Montero et al., 2012). These(C) Schematic representation of experimental procedures. Lung endothelial cell
therapy. Mice showing established lung metastasis 7 weeks after tail-vein inject
CD31+ endothelial cells were purified from dissociated lung tissue by flow cytom
(D) TNF-a expression in isolated CD31+ lung endothelial cells from chemothe
averages ± SEM.
(E) TNF-a expression in the indicated primary cells upon doxorubicin chemotherap
95% confidence interval for qRT-PCR analysis. Data are representative of three
(F)CXCL1 expression in LM2 cancer cells treated with vehicle or TNF-a for 2 hr in t
NF-kB pathway. Data represent averages ± SEM.
(G and H) Representative images of S100A9 expression by immunohistoche
AC-chemotherapy-treated mice, with or without anti-TNF-a blocking antibody (infl
starting at 10 weeks after tumor inoculation, with PBS vehicle, AC chemotherapy (
averages ± SEM; n = 3–5 mice/group. p values were calculated by Student’s t te
(I) Immunohistochemical analysis of TNF-a expression in human primary breast
(J) Stromal rich areas containing lymphatic vessels, blood vessels and fibroblast
treatment. Magnified fields from images taken at 403 magnification.
(K) Comparison of stromal TNF-a expression score in paired breast tumors before
paired test, comparing pre- and posttreatment levels from each patient.
See also Figure S6.findings accentuate the clinical relevance of CD11b+Gr1+ in
rendering chemotherapy ineffective and promoting metastasis.
Our findings argue that although therapy induced inflamma-
tion is a predominant feature of the use of chemotherapy,
disrupting the CXCL1 driven paracrine axis could improve
therapeutic response in existing lesions and also suppress
metastasis, even at an advanced stage of tumor progression.
CXCR2 receptor antagonists are in clinical trials for chronic
inflammatory diseases (Chapman et al., 2009), and we show
that these agents are a promising pharmacological approach
in metastatic breast cancer when combined with standard
chemotherapeutic regimen. The effective combination of
chemotherapy with CXCR2 inhibitors at the metastatic site in
our preclinical models underscores the potential application of
this therapy to limit disseminated tumor burden. Moreover, the
important role of CXCR2 in pancreatic adenocarcinoma models
(Ijichi et al., 2011) and of S100A8/9 in colorectal cancer (Ichikawa
et al., 2011) suggest that the relevance of targeting the CXCL1/2-
S100A8/9 axis may extend beyond breast cancer.
In conclusion, our results provide mechanistic insights into the
link between twomajor hurdles in treating breast cancer: chemo-
resistance and metastasis. Our findings functionally unify three
important inflammatory modulators, TNF-a, CXCL1/2, and
S100A8/9, in a tumor-stroma paracrine axis that provides a
survival advantage to metastatic cells in stressed primary and
metastatic microenvironments. This raises the possibility of
clinically targeting this axis both to limit the dissemination of
cancer cells and to diminish drug resistance.EXPERIMENTAL PROCEDURES
Flow Cytometry Analysis
Whole tumors or lung tissues were dissected, cut into small pieces, and disso-
ciated by using 0.5% collagenase Type III (Worthington Biochemical) and 1%
Dispase II (Roche) in PBS for 1–2 hr. Resulting single-cell suspensions were
washed in PBS with 2% heat-inactivated fetal calf serum and filtered through
70 mm nylon mesh. Cell fractions were incubated for 10 min at 4C with anti-
mouse Fc block CD16/32 antibody (2.4G2 BD) in PBS containing 1% BSA to
avoid nonspecific antibody binding. Cells were subsequently washed in
PBS/BSA and stained with either Ig controls or fluorophore conjugateds were purified from LM2 tumor-bearing mice that were treated with chemo-
ion of LM2 cells were either treated with vehicle (saline) or AC chemotherapy.
etry.
rapy-treated tumor-bearing mice. n = 2–4 mice per group. Data represent
y treatment for 16 hr as determined by qRT-PCR analysis. Error bars represent
independent experiments.
he presence of a 100 mMNBD (NEMO binding domain) inhibitory peptide of the
mistry and quantitation of S100A9 positive cells in tumors from control or
iximab). Mice bearing CN34LM1 tumors were treated once weekly for 5 weeks
chemo), or chemotherapy plus anti-TNF-a antibody. Scale bar, 32 mm. Data are
st.
tumor before and after chemotherapy treatment. Scale bar, 120 mm.
s with high TNF-a staining from primary breast tumors after AC chemotherapy
and after chemotherapy. n = 8 patients. p value was determined byWilcoxon’s
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Figure 7. Pharmacological Inhibition of CXCL1 Signaling Sensitizes Cancer Cells to Chemotherapy in Metastatic Breast Cancer
(A and B) Schematic treatment flow (A), and tumor growth (B) of LM2 tumors in mice treated with PEG vehicle or CXCR2 inhibitor for the indicated periods (blue
boxes) and treatment with saline vehicle or AC chemotherapy at the indicated days (red arrows). Data represent average expression ± SEM; n = 10–13 mice per
group. p values were determined by Student’s t test. *p = 0.02, **p = 0.007.
(C and D) Lung metastasis in MDA231-LM2 and CN34-LM1 orthotopic xenograft models undergoing treatment (C) Representative images of lung sections
stained for vimentin expression marking metastatic cancer cells. Scale bars, 100 mm. (D) Quantitation of metastasis based on number of cancer cells in lung
sections. Data are average foci per FOV ± SEM; n = 5–10 mice per group. Whiskers represent minimum and maximum values. p values were determined by two-
tailed Wilcoxon rank-sum test.
(E) Model showing how CXCL1 paracrine interactions promote resistance to chemotherapy and metastasis in breast tumors and lung microenvironment.
Genotoxic agents such as doxorubicin, cyclophosphamide, and paclitaxel limit the survival of cancer cells but also increase TNF-a production from endothelial
cells. TNF-a enhances CXCL1/2 expression in cancer cells. Other modes of CXCL1/2 upregulation in cancer cells include 4q21 amplification and overexpression.
CXCL1/2 from cancer cells recruit CD11b+Gr1+ myeloid cells that express CXCR2 (receptors for CXCL1/2). Myeloid cells recruited by CXCL1/2 thereby enhance
viability of cancer cells through S100A8/9 factors.
See also Figure S7.antibodies in MACS buffer (0.5% BSA, 2 mM EDTA in PBS). Data acquisition
was performed on a FACS Calibur (BD Biosciences) or Cytomation CyAn
(Beckman Coulter) and analysis was done by using Flowjo version 9
(Tree Star).
Animal Studies
All experiments using animals were done in accordance to a protocol
approved by Memorial Sloan-Kettering Cancer Center (MSKCC) Institutional
Animal Care and Use Committee (IACUC). S100a9+/+ and S100a9/mice
(Hobbs et al., 2003), NOD-SCID NCR (NCI), athymic NCR nu/nu (Harlan), NIHIII
homozygous nu/nu (Charles River), C57BL/6 (Jackson Labs), FVB/N (Charles
River) female mice aged between 5–7 weeks were used. Autochthonous
MMTV driven-polyoma virus middle T transgenic mice (Kim et al., 2009)176 Cell 150, 165–178, July 6, 2012 ª2012 Elsevier Inc.were utilized for isolation of primary PyMT and bone-marrow-derived cells.
Refer to Extended Experimental Procedures for detailed assays, drug treat-
ment, and bone marrow transplantation.
Patient Samples
Paraffin embedded tissue microarrays containing primary breast cancer
samples (IMH-364) and lymph node metastases (BRM481) were purchased
from Imgenex and Pantomics, respectively. Paraffin embedded tissue
microarrays and sections from lung metastases and primary breast tumor
cores before and after chemotherapy treatment were acquired from the
MSKCC Department of Pathology in compliance with protocols approved by
the MSKCC Institutional Review Board (IRB). Staining details provided in
Extended Experimental Procedures.
Bioinformatic and Statistical Analysis
All bioinformatic analyses were conducted in R. Microarray data from human
tumor data sets were processed as described (Zhang et al., 2009). Survival
curves for patients were calculated by using Kaplan-Meier method and differ-
ences between the curves were determined by log rank test. All other experi-
ments were analyzed by using two-sided Wilcoxon rank-sum test or unpaired
two-sided t test without unequal variance assumption unless specified.
p values % 0.05 were considered significant. See Extended Experimental
Procedures for details.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and five tables and can be found with this article online at doi:10.1016/
j.cell.2012.04.042.
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